In 2004, California voters approved $3 billion to establish the California Institute for Regenerative Medicine, aiming to advance treatments for rare and complex diseases. More than two decades later, in 2026, the institute announced its first therapy—a treatment for children with a rare immune disorder—marking a significant milestone for the families involved. However, the lengthy development timeline of 22 years has raised concerns about the pace of medical research, especially for those facing urgent health challenges like amyotrophic lateral sclerosis (ALS), cancer, and Alzheimer’s disease.

With the recent passage of Proposition 38, California plans to invest an additional $8.4 billion in medical research. Advocates of the initiative argue that this funding must come with expectations of faster development and delivery of treatments, highlighting that scientific advancements and new technologies offer opportunities to accelerate progress. They point to the COVID-19 pandemic response as a model for rapid innovation: when the novel coronavirus emerged in January 2020, vaccines became available to the public by December, aided in part by early-stage artificial intelligence (AI) tools.

Today’s more sophisticated AI systems analyze vast and complex datasets, map genetic mutations, and assist in drug design by identifying subtle patterns often missed by human researchers. Such technologies have demonstrated potential benefits, from detecting breast cancers overlooked by diagnosticians to improving drug screening efficiency. In parallel, the Food and Drug Administration encourages the use of synthetic organoids—lab-grown miniature human organs—for drug testing to identify toxic reactions earlier than traditional animal models.

The reliance on animal testing has been criticized for contributing to lengthy development timelines and high failure rates. Studies indicate that approximately 90% of drugs that succeed in animal trials fail when tested in humans. For example, researchers note that hundreds of drugs that reversed Alzheimer’s pathology in mice over three decades ultimately failed in human trials, representing significant setbacks and wasted time. The California Institute for Regenerative Medicine’s own experience with setbacks due to faulty animal testing trials has fueled calls to rethink research methods.

Some research institutions have begun adapting to modern approaches. The regenerative medicine institute itself is aiming to shorten timelines by linking funding to milestones and pursuing strict two-year deadlines for clinical trials. Stanford University emphasizes human-tissue screening to bypass animal testing by validating drugs on human cells directly, while Scripps Research Institute integrates extensive datasets with AI workflows to reduce analysis time from months to days.

Proponents argue that California’s public funding should require adoption of these faster, human-centered research pipelines and promote data sharing to avoid duplication and accelerate collective progress. They suggest that accountability milestones be mandatory for all publicly funded projects, including basic research, preventing open-ended timelines and encouraging measurable advances within set periods.

Yet some caution that rapid development must be balanced with rigorous evaluation to ensure safety and efficacy. The argument centers on how to best leverage new technologies while maintaining thorough scientific standards. Advocates maintain that public investment presents a unique opportunity to drive systemic change in research culture by demanding transparency, collaboration, and efficiency.

As California prepares to allocate billions more to medical research, many emphasize the urgency of aligning funding with strategies that deliver timely results. Patients and families affected by life-threatening conditions are increasingly questioning what is being done to shorten the lengthy wait for effective treatments. The call is clear: the new investment should not only fuel discovery but also chart a faster, more accountable path from research to real-world therapies.